about
First line vs delayed transplantation in myeloma: Certainties and controversiesBortezomib and dexamethasone as salvage therapy in patients with relapsed/refractory multiple myeloma: analysis of long-term clinical outcomes.Translocations at 8q24 juxtapose MYC with genes that harbor superenhancers resulting in overexpression and poor prognosis in myeloma patients.Coexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocationsThe genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD)Global methylation analysis identifies prognostically important epigenetically inactivated tumor suppressor genes in multiple myeloma.Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms.Role of consolidation therapy in transplant eligible multiple myeloma patients.Maintenance therapy in newly diagnosed multiple myeloma: current recommendations.The impact of intra-clonal heterogeneity on the treatment of multiple myeloma.Biology and treatment of myeloma.Therapeutic targeting of hypoxia and hypoxia-inducible factor 1 alpha in multiple myeloma.Current and emerging triplet combination therapies for relapsed and refractory multiple myeloma.HIF-1α inhibition blocks the cross talk between multiple myeloma plasma cells and tumor microenvironment.Safety issues and management of toxicities associated with new treatments for multiple myeloma.Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma.PET/CT Improves the Definition of Complete Response and Allows to Detect Otherwise Unidentifiable Skeletal Progression in Multiple Myeloma.Peripheral neuropathy induced by subcutaneous bortezomib-based induction therapy for newly diagnosed multiple myeloma.The impact of response on bone-directed therapy in patients with multiple myeloma.Biologically defined risk groups can be used to define the impact of thalidomide maintenance therapy in newly diagnosed multiple myeloma.Bortezomib-based therapy combined with high cut-off hemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment.Correlation between eight-gene expression profiling and response to therapy of newly diagnosed multiple myeloma patients treated with thalidomide-dexamethasone incorporated into double autologous transplantation.Serum free immunoglobulin light chain evaluation as a marker of impact from intraclonal heterogeneity on myeloma outcome.The utility of newer imaging techniques as predictors of clinical outcomes in multiple myeloma.Response and biological subtype of myeloma are independent prognostic factors and combine to define outcome after high-dose therapy.The value of 18F-FDG PET/CT after autologous stem cell transplantation (ASCT) in patients affected by multiple myeloma (MM): experience with 77 patients.Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myelomaSingle-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myelomaBortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myelomaLong-term results of thalidomide and dexamethasone (thal-dex) as therapy of first relapse in multiple myelomaMultiple myeloma, venous thromboembolism, and treatment-related risk of thrombosisThe impact of long-term lenalidomide exposure on the cellular composition of bone marrowLong-term follow-up after autologous stem cell transplantation for light- and heavy-chain deposition diseasePatient with ataxia telangiectasia who developed acute myeloid leukemiaOsteonecrosis of the jaws in newly diagnosed multiple myeloma patients treated with zoledronic acid and thalidomide-dexamethasoneThe acetyltransferase GCN5 maintains ATRA-resistance in non-APL AMLThe risk of infections in multiple myeloma before and after the advent of novel agents: a 12-year surveyFrailty impairs the feasibility of induction therapy but not of maintenance therapy in elderly myeloma patients: final results of the German Maintenance Study (GERMAIN)Frequency of infections in 948 MPN patients: a prospective multicenter patient-reported pilot study
P50
Q26745957-45B0463F-FC54-4D50-AC6A-86ADA4F7CEBEQ33409172-9C9CF1B3-516B-4F0E-8BDC-08E9B3BE4B56Q34410261-2B03F8C3-4219-49C5-B4A6-9DBF0313C799Q35081172-1B3B325E-FF97-429C-992C-8F6E6C4F7F4EQ36962747-1B5D361E-5D65-4C0F-A34B-EF6E21ADF885Q37006888-BE4A6C30-766C-4CC0-B942-DA7D9C0816B7Q37564751-1F0C4F70-6491-4BBA-ACF8-4512CBF120ACQ38153542-2E7B20BA-B3C7-4880-BCF4-843220DCCA5AQ38191975-541D15E4-8762-4C15-94D9-FDD4CE5D30F1Q38192044-03038E30-B55F-4E7D-977A-B17991047DE9Q38285267-CE54F911-B936-42C7-94FF-CF055F904263Q38305518-6CFD8597-8915-4916-91FE-0067F4569315Q38658649-1D73397F-0028-4C5A-9411-E85EEB241756Q38953187-94BB57BF-A7B1-4816-BC0C-6DECD4DD32A4Q39100317-C78BC3C4-AB55-4A2C-BB2F-FB64818D5B2FQ40633414-641B9E31-5A1C-422F-A38C-E93EF4B7EE84Q41666443-0BAF3D50-BEC7-401D-8353-4DB279D834F4Q42979846-27DCA69D-FFE6-4E79-A0CA-3DBF0B12E672Q43806533-8A22DBA1-64A1-423D-AA82-0A6A8158EE49Q44690816-44F2A697-5E01-4375-9A7F-4ED366D486D3Q50934141-4EDCD8AA-CE48-47A8-B673-19F13DAC6E5FQ51812800-9DBB1145-32C2-4A93-8112-F3A747742BAFQ52839837-81444236-62AB-4DD1-AD4D-8750448FCE6BQ53072763-2DE3FDCA-12C4-4D02-88B8-42A642813FB3Q53122662-E6E8F65F-47D2-4E7A-AD1E-9EEA02C322E8Q53134754-CA55C5C2-3336-4948-BAD2-F6FC95068427Q56967485-F1E7AFE6-066D-4A35-85A6-8864A6737AC8Q56973515-5D230A72-B30B-4827-A289-B7459FB28A95Q56981141-F58709BA-1C8B-40A1-91CF-8402B4B42CBFQ56982314-E6901622-C61D-4540-ABE4-2E17F4B83C67Q56986346-161247C0-736A-4136-B832-DDCE1F574FB1Q57903975-5FA0F62A-D0A4-485A-BF9C-7815F8EB225DQ57904003-12EED125-3985-43BA-A7EF-E43639BEE5F6Q57904024-40FDD468-0422-457F-A34A-DEF4D571ACA0Q57904055-7F8C3950-8DE3-4E31-828D-A3ABA1F26505Q90426515-5D13ED0B-F7B4-4976-9C7A-2C0ACC9EE79AQ91214479-80E65B9E-71EB-43BB-AC07-4174F3CBD0C6Q91589752-122D52F3-EDDC-42D7-8905-09AE2019CA29Q96032684-B7FC9872-4175-4CFC-899C-E2FA197FCE84
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Annamaria Brioli
@ast
Annamaria Brioli
@en
Annamaria Brioli
@es
Annamaria Brioli
@nl
type
label
Annamaria Brioli
@ast
Annamaria Brioli
@en
Annamaria Brioli
@es
Annamaria Brioli
@nl
prefLabel
Annamaria Brioli
@ast
Annamaria Brioli
@en
Annamaria Brioli
@es
Annamaria Brioli
@nl
P106
P1153
15130771200
P31
P496
0000-0002-4072-7592